Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia.

ABSTRACT:

Introduction

There has been a growing recognition on the importance of diversity in clinical trials. Existing research has highlighted a significant demographic imbalance. Amidst this renewed focus on diversity, it is crucial to acknowledge that Asia comprises over half of the world's population. Given the region's demographic significance, we sought to compare various characteristics and growth rates for trials with sites in Asia against those without any sites in Asia.

Methods

We performed comprehensive analyses of industry-sponsored phase 2 and 3 oncology trials registered at Clinicaltrials.gov, using drugs or biologics as investigational agents and executed between 1 January 2018 and 31 December 2022. We applied the compound annual growth rate (CAGR) as an analytical too

SUBMITTER: Habr D 

PROVIDER: S-EPMC10881454 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature